VERAXA Biotech (NASDAQ: VRXA) announced new in vitro proof-of-concept data supporting its novel BiTAC(TM)-ADC technology platform, which is designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells and achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components.
VERAXA said the findings further validate the potential of its BiTAC-ADC platform and complement its BiTAC-TCE technology, providing the company with two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026. The full press release is available at https://ibn.fm/QiPhH.
The BiTAC-ADC platform represents a significant advancement in antibody-drug conjugate (ADC) technology. Traditional ADCs deliver a toxic payload directly to cancer cells via antibodies targeting tumor-specific antigens, but off-target toxicity remains a challenge. VERAXA's approach uses two separate components that are systemically inactive until they combine at the tumor site, potentially reducing damage to healthy tissues. The proof-of-concept data in breast cancer cell lines and 3D spheroids provides early validation of this mechanism.
VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
The announcement is important because it addresses a key limitation of current cancer therapies: the inability to selectively target tumor cells without harming healthy tissue. If further validated, the BiTAC-ADC platform could lead to safer and more effective treatments for a range of solid tumors. The company's presence at the BIO International Convention signals its intent to seek partners for further development, potentially accelerating the path to clinical trials. Investors and researchers will be watching for additional data as the platform progresses.
For more information about VERAXA Biotech, including the latest news and updates, visit the company’s newsroom at https://ibn.fm/VRXA.
